The 9 most recent market catalysts affecting $LAKE, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 24, 2026
Corporate Catalyst
Bullish
Impact 75
Lakewood-Amedex Biotherapeutics Announces First Patient Dosed In Phase 2a Trial Of Nu-3 For Infected Diabetic Foot Ulcers; Topline Data Expected In Q1 2027
The initiation of a Phase 2a trial for Nu-3 is a critical de-risking event for Lakewood-Amedex Biotherapeutics, as it moves the drug closer to potential commercialization. Positive…
Sep 18, 2026
Corporate Catalyst
Neutral
Impact 75
Lakewood-Amedex Registers Resale Of Up To 4,512,400 Shares Of Common Stock By Selling Stockholder
Lakewood-Amedex is filing to register an additional 4,512,400 shares of common stock for resale by a selling stockholder. This significant increase in registrable shares stems from…
Sep 18, 2026
Corporate Catalyst
Bullish
Impact 75
Lakewood-Amedex Biotherapeutics Says It Obtained IRB Approvals, Site Readiness To Begin Phase 2a Trial Of Nu-3 In Infected Diabetic Foot Ulcers
This news is a significant positive catalyst for Lakewood-Amedex Biotherapeutics as it marks a crucial step forward in the development of Nu-3. Advancing to Phase 2a trials indicat…
Sep 14, 2026
Corporate Catalyst
Bearish
Impact 55
DA Davidson Maintains Buy on Lakeland Industries, Lowers Price Target to $15
DA Davidson analyst Michael Shlisky maintained a 'Buy' rating on Lakeland Industries but lowered the price target from $18 to $15. This action signals that while the analyst still …
Sep 9, 2026
Corporate Catalyst
Bearish
Impact 95
Lakeland Industries Q2 EPS $(0.50) Misses $(0.05) Estimate, Sales $50.139M Miss $51.483M Estimate
Lakeland Industries (LAKE) announced Q2 results that fell significantly short of analyst expectations, with EPS missing by a staggering 900% and sales missing by 2.61%. This substa…
Aug 31, 2026
Corporate Catalyst
Bullish
Impact 75
Lakewood-Amedex Biotherapeutics shares are trading higher after the company received a notice of allowance for a U.S. patent titled "ANTIMICROBIAL COMPOUNDS, COMPOSITIONS, AND USES THEREOF"
This patent allowance is a significant positive catalyst for Lakewood-Amedex, as it protects their core technology and enhances their valuation. It reduces competitive threats and …
Aug 25, 2026
Corporate Catalyst
Bullish
Impact 75
Lakeland Industries Announces New Contract Awards Across South America, Including Callao Fire Department Tender And Multi-Year SONDEL Utility Agreement; Terms Not Disclosed
This announcement is a significant positive catalyst for Lakeland Industries (LAKE). New contract awards, especially multi-year agreements, provide revenue visibility and demonstra…
Aug 24, 2026
Corporate Catalyst
Bullish
Impact 75
Lakefront Biotherapeutics Says FDA Granted Orphan Drug Designation To Gamgertamig For Treatment Of Pemphigus
The Orphan Drug Designation (ODD) granted to Gamgertamig is a significant positive catalyst for Lakefront Biotherapeutics. ODD provides incentives such as tax credits, user fee wai…
Jul 22, 2026
Corporate Catalyst
Bullish
Impact 75
Lakewood-Amedex Biotherapeutics shares are trading higher after the company announced resistance data for Nu-3.
The positive resistance data for Nu-3 is a significant corporate catalyst for Lakewood-Amedex, directly impacting its stock price positively. This type of data is crucial in drug d…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.